1. Key Insights

2. Report Introduction

3. Liver Fibrosis Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Liver Fibrosis in 2019
3.2. Patient Share (%) Distribution of Liver Fibrosis in 2032

4. Executive Summary of Liver Fibrosis

5. Disease Background and Overview: Liver Fibrosis
5.1. Introduction of Liver Fibrosis
5.2. Fibrogenesis in Liver Fibrosis
5.3. Etiology of Liver Fibrosis
5.3.1. Metabolic disorders: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
5.3.2. Genetic disorders
5.3.3. Alcohol
5.3.4. Drugs
5.3.5. Cholestasis
5.3.6. Viral hepatitis
5.3.7. Parasitic infections
5.3.8. Cryptogenic causes
5.4. Pathophysiology of Liver Fibrosis
5.4.1. Cell types in liver fibrosis
5.5. Diagnostic Approach for Liver Fibrosis
5.5.1. General approach to evaluate liver fibrosis
5.5.2. Liver biopsy and histologic assessment of the liver
5.5.3. Classification of liver histology
5.5.4. Indirect markers of fibrosis
5.5.5. Direct markers of fibrosis
5.5.6. Radiologic Modalities to Estimate Fibrosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.3.1. United States
6.3.2. EU-5 Countries
6.3.3. Japan
6.4. Total Diagnosed Prevalent cases of Liver Fibrosis in the 7MM
6.5. The United States
6.5.1. Total diagnosed prevalent cases of Liver fibrosis in the United States
6.5.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the United States
6.5.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the United States
6.6. Major Five European Countries
6.6.1. Total diagnosed prevalent cases of Liver fibrosis in the EU-5
6.6.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5
6.6.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the EU-5
6.7. Japan
6.7.1. Total diagnosed prevalent cases of Liver fibrosis in Japan
6.7.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan
6.7.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan

7. Patient Journey

8. KOL Views

9. Appendix
9.1. Bibliography
9.2. List of Abbreviations

10. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables
Table 1 : Summary of Liver Fibrosis Epidemiology (2019-2032)
Table 2 : Total Diagnosed Prevalent cases of Liver Fibrosis in the 7MM, in ‘000' (2019-2032)
Table 3 : Total Diagnosed Prevalent Cases of Liver Fibrosis in the US, in ‘000' (2019-2032)
Table 4 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the US, in ‘000' (2019-2032)
Table 5 : Total Diagnosed Prevalent Cases of Liver Fibrosis in NASH in the US, in ‘000' (2019-2032)
Table 6 : Total Diagnosed Prevalent Cases of Liver Fibrosis in the EU-5, in ‘000' (2019-2032)
Table 7 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5, in ‘000' (2019-2032)
Table 8 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Germany, in ‘000' (2019-2032)
Table 9 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in France, in ‘000' (2019-2032)
Table 10 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Italy, in ‘000' (2019-2032)
Table 11 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Spain, in ‘000' (2019-2032)
Table 12 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the UK, in ‘000' (2019-2032)
Table 13 : Total Diagnosed Prevalent cases of Liver Fibrosis in NASH in EU-5, in ‘000' (2019-2032)
Table 14 : Total Diagnosed Prevalent cases of Liver Fibrosis in Japan, in ‘000' (2019-2032)
Table 15 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan, in ‘000' (2019-2032)
Table 16 : Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan, in ‘000' (2019-2032)
Table 17 : List of abbreviations

List of Figures
Figure 1: Liver Architecture in Healthy Liver and Fibrosis. (A) Normal liver (B) Injury to hepatocytes due to any of Several Causes, Such as Alcohol, Drug, Genetic Predisposition, etc., Activates the Wound Healing Fibrogenic Response
Figure 2: Drivers Predisposing the Liver to Fibrosis
Figure 3: The TGF-? Signaling Pathway in Hepatic Stellate Cells
Figure 4: Summary of Important Pathways in the Progression of NAFLD to NASH
Figure 5: Alcohol Metabolism in the Liver
Figure 6: Metabolism of Drugs and Other Xenobiotics in the Liver
Figure 7: Pathophysiology of Liver Fibrosis
Figure 8: Aspartate Aminotransferase-to-Platelet-Ratio Index (APRI)
Figure 9: The Fib4 Represents an Easy-to-use Test for Predicting Severe Hepatic Fibrosis or Cirrhosis.
Figure 10: The FibroIndex is a Complicated Calculation That Requires a Platelet Count, Aspartate Aminotransferase (AST) Level, and Gamma Globulin Level.
Figure 11: The Forns Index Incorporates Easy-to-obtain Parameters but Requires a Highly Complicated Calculation
Figure 12: HepaScore (FibroScore)
Figure 13: Castera Transient Elastography Cutoffs Correlating With Metavir Fibrosis
Figure 14: Castera Transient Elastography Cutoffs Correlating With Metavir Fibrosis
Figure 15: Ziols Transient Elastography Cutoffs Correlating with Metavir Fibrosis
Figure 16: Ziols Transient Elastography Cutoffs Correlating with Metavir Fibrosis
Figure 17: Castera and Ziol Cut-offs for Metavir F3 Fibrosis Score
Figure 18: Total Diagnosed Prevalent Cases of Liver Fibrosis in the 7MM, in ‘000' (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of Liver Fibrosis in the US, in ‘000' (2019-2032)
Figure 20: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the US, in ‘000' (2019-2032)
Figure 21: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the US, in ‘000' (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of Liver Fibrosis in the EU-5, in ‘000' (2019-2032)
Figure 23: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5, in ‘000' (2019-2032)
Figure 24: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the EU-5, in ‘000' (2019-2032)
Figure 25: Total Diagnosed Prevalent Cases of Liver Fibrosis in Japan, in ‘000' (2019-2032)
Figure 26: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan, in ‘000' (2019-2032)
Figure 27: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan, in ‘000' (2019-2032)
Figure 28: Patient Journey